2nd Feb 2007 07:00
Henderson Morley PLC02 February 2007 2 February 2007 HENDERSON MORLEY PLC (AIM) Business: Drug Discovery Company Issue of Equity Henderson Morley plc ("Henderson Morley" or "the Company") announces that theBoard has, today, issued and allotted, conditional upon Admission, a total of 30million new Ordinary shares through a Placing to investors at a price of 2p pershare, raising £600,000 for the Company. The total number of shares in issue isnow 491,928,631. The purpose of this Placing is to provide the Company with working capital tocontinue to invest in its ongoing scientific programme. In this respect, theCompany is pleased to announce that three new scientists have joined itsresearch facility at Birmingham. These new appointments will be focussing on thedevelopment of the PREPS vaccine technology as a cancer immunotherapeutic; andthe further development of the vaccine candidates for the prevention of Koiherpes. Henderson Morley anticipates being in a position to update shareholders shortlyon the progress being made in respect of the Koi herpes vaccine currently beingundertaken at the University of Idaho, USA. Application will be made for the new shares to be admitted to AIM and trading inthe new shares is expected to commence as soon as practicable. --ENDS-- Copies of this announcement will be available free of charge to the public atthe Company's registered office at Metropolitan House, 2 Salisbury Road,Moseley, Birmingham, B13 8JS and at the offices of Brewin Dolphin SecuritiesLtd, 34 Lisbon Street, Leeds LS1 4LX for 14 days. Enquiries: HENDERSON MORLEY PLC Tel: 0121 442 4600Andrew Knight, Chairman BISHOPSGATE COMMUNICATIONS LTD Tel: 020 7562 3350Maxine Barnes Mobile: 07860 489571Nick Rome BREWIN DOLPHIN SECURITIES LTD Tel: 0113 241 0126Neil Baldwin This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
HML.L